Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Cigna Group CEO David Cordani said the company will make investments this year to improve patient and provider experiences ...

Reports Q4 revenue $65.65B, consensus $63.18B. “While higher medical costs in our stop loss product impacted fourth quarter earnings, we are ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

Negotiated professional fees are lower among primary care physicians practicing in independent settings than for those who ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...